الفهرس 
Metabolic Syndrome
Biomarkers in Metabolic SyndromeOnly 14 pages are availabe for public view
 |  | from | 294 |  |  |
| | | from | 294 | | |
Abstract
SUMMARY Metabolic syndrome is a disorder characterized by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressure, high serum TGs, low LDL, high cholesterol levels, and elevated FBS. Some studies showed that increased numbers of MetS risk components lead to worsening CVD outcomes and risk factors. Patients with inflammatory rheumatic diseases as RA, SLE & PsA have an increased risk of developing cardiovascular manifestations. The high risk of CV pathology in these patients is not only due to traditional CV risk factors (age, gender, family history, smoking, sedentary lifestyle, cholesterol), but also to chronic inflammation and autoimmunity.Interleukin 10 is anti-inflammatory cytokine; low levels of IL-10 are associated with MetS. Many patients with rheumatic diseases had subclinical cardiac affection so, early detection of cardiac affection limit long term morbidity and mortality in these patients. The aim of this work was to study the relation of MetS to the disease activity, clinical and laboratory data of RA, SLE & PsA patients, also to assess the risks factors for MetS in these rheumatic diseases and to detect serum level of IL 10 and its relation to disease activity of these rheumatic diseases and MetS. This study was done on 90 patients divided into 3 groups as: group I (RA): 30 RA patients diagnosed according to the ACR/EULAR 2010 criteria. (129)